



MAR 08 2004

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

Application Number	09/760,274
Filing Date	January 12, 2001
First Named Inventor	John Sinden
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	GJE-21D2

Sheet

1

of

2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
mw	U1	US-2003/0147873 A1	08-07-2003	Sinden et al.	All
mw	U2	US-2002/0123143 A1	09-05-2002	Toma et al.	All
mw	U3	US-6,399,384 B1	06-04-2002	Jat	All
mw	U4	US-6,528,306 B1	03-04-2003	Snyder et al.	All
mw	U5	US-5,817,773	10-06-1998	Wilson et al.	All
mw	U6	US-5,690,927	11-25-1997	Major et al.	All
mw	U7	US-09/913,443	08-14-2001	Proteogen (patent application)	All
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
mw	F1	WO 00/50588 A3	08-31-2000	Reneuron Limited	All	
	F2	WO 98/07841 A1	02-26-1998	Univ. Mass.	All	
	F3	WO 93/18137 A1	09-16-1993	Systemix, Inc.	All	
	F4	WO 92/11355 A1	07-09-1992	Regents. of Univ. Calif.	All	
mw	F5	WO 89/09816 A1	10-19-1989	Mass. Inst. Tech.	All	
	F6					
	F7					

Examiner
SignatureDate
Considered

5-21-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



MAR 08 2004

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	09/760,274
			Filing Date	January 12, 2001
			First Named Inventor	John Sinden
			Group Art Unit	1632
			Examiner Name	Michael C. Wilson
			Attorney Docket Number	GJE-21D2
Sheet	2	of	2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mw	R1	ANDERSON, W.F. "Human gene therapy" <i>Nature</i> , 1998, 392:25-30.	
	R2	ALLAY, J.A. <i>et al.</i> "LacZ and interleukin-3 expression <i>in vivo</i> after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors" <i>Human Gene Therapy</i> , 1997, 8:1417-1427.	
	R3	CHOPP, M. <i>et al.</i> "Adult bone marrow transplantation for treatment of stroke in adult mice" <i>Society for Neuroscience</i> , 1999, 25:1309, abstract no. 528.2 (abstract).	
	R4	CEPKO, C.L. "Immortalization of neural cells via retrovirus-mediated oncogene transduction" <i>Ann. Rev. Neurosci.</i> , 1989, 12:47-65.	
	R5	FREDERIKSEN, K. <i>et al.</i> "Immortalization of Precursor Cells from the Mammalian CNS" <i>Neuron</i> , 1988, 1:439-448.	
	R6	JAT, P.S. "Direct derivation of conditionally immortal cell lines from an H-2K ^b -IsA58 transgenic mouse" <i>Proc. Natl. Acad. Sci. USA</i> , 1991, 88:5096-5100.	
	R7	MAJOR, E.O. <i>et al.</i> "Establishment of a line of human fetal glial cells that supports JC virus multiplication" <i>Proc. Natl. Acad. Sci. USA</i> , 1985, 82:1257-1261.	
	R8	MEZEY, E. and K.J. CHANDROSS "Bone marrow: a possible alternative source of cells in the adult nervous system" <i>Euro. J. Pharmacology</i> , 2000, 405:297-302.	
	R9	PALU, G. <i>et al.</i> "In pursuit of new developments for gene therapy of human diseases" <i>J. Biotechnology</i> , 1999, 68:1-13.	
	R10	WYLLIE, F.S. <i>et al.</i> "A phenotypically and karyotypically stable human thyroid epithelial line conditionally immortalized by SV40 large T antigen" <i>Cancer Res.</i> , 1992, 52:2938-2945.	
	R11	Stem Cells: Scientific Progress and Future Research Directions, June 2001, Introductory Chapter and Chapters 8 and 11.	
	R12		
	R13		

Examiner Signature		Date Considered	5.20.04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.